[{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SLC-3010","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"Selecxine \/ GenScript ProBio"}]

Find Clinical Drug Pipeline Developments & Deals by Selecxine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : SLC-3010 selectively stimulates anti-tumor immune response and the efficacy of SLC-3010 in eradication of various types of tumor was thoroughly demonstrated through various in vitro and in vivo experiments.

                          Brand Name : SLC-3010

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 23, 2022

                          Lead Product(s) : SLC-3010

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : GenScript ProBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank